Lomitapide and Ibrexafungerp: Interaction Details
- Lomitapide
- Juxtapid
- Ibrexafungerp
- Brexafemme
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS
Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
- Dr. Brian Staiger, PharmD, BCPS, is a clinical pharmacist and pharmacotherapy specialist.
- AI-assisted, written
- AI is used only to summarize verified clinical information, never the open internet.
- Editorial policy
- How we build our interaction pages →
- Our AI policy →
A close look at the Lomitapide and Ibrexafungerp interaction:
Ibrexafungerp
- Brexafemme
We don't have a drug information page for Ibrexafungerp yet. Have a question about Ibrexafungerp? Ask a pharmacist, free →
What Happens When You Take Lomitapide With Ibrexafungerp
What can happen when they are taken together (rated Major)
Increased lomitapide exposure
Interaction Deep Dive
A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →
Lomitapide is a , so giving it together with a weak CYP3A4 can raise lomitapide exposure. When a weak CYP3A4 inhibitor is used at the same time, the maximum recommended lomitapide dosage is 10 mg for ages 2 to 10 years, 20 mg for ages 11 to 17 years, and 30 mg for ages 18 years and older.
The schedule during of a weak CYP3A4 inhibitor depends on age. For ages 2 to 10 years, the dose starts at 2 mg (weeks 0 to 8), moves to 5 mg (weeks 9 to 12) and 10 mg (weeks 13 to 16), and reaches 20 mg from week 17 onward; higher doses are not recommended.
For ages 11 to 15 years, the dose starts at 2 mg (weeks 0 to 4), then 5 mg (weeks 5 to 8), 10 mg (weeks 9 to 12), 20 mg (weeks 13 to 16), and 40 mg from week 17 onward; the 60 mg dose is not recommended. For ages 16 to 17 years, the dose starts at 2 mg (weeks 0 to 2), then 5 mg (weeks 3 to 6), 10 mg (weeks 7 to 10), 20 mg (weeks 11 to 14), and 40 mg from week 15 onward; the 60 mg dose is not recommended.
Patients aged 18 years and older follow the same titration pattern as the 16 to 17 year group, but the 60 mg dose is permitted after week 15. If a weak CYP3A4 inhibitor is started in a patient who is on a stable lomitapide dosage, the lomitapide dose should be cut in half.
Careful titration can then be considered, guided by LDL-C response and safety/tolerability, up to half of the maximum recommended dosage. The exception is coadministration with oral contraceptives only, in which case the maximum recommended lomitapide dose is about two thirds of the maximum recommended dose.1
The Lomitapide and Ibrexafungerp Interaction, Explained
Ibrexafungerp can make lomitapide build up in your body. Your body uses an enzyme called to clear lomitapide, and ibrexafungerp slows that enzyme a little. More lomitapide in the blood can raise the chance of side effects, especially liver problems and stomach upset such as nausea, diarrhea, or cramping.
Because of this, your prescriber will likely keep your lomitapide dose lower while you take both. Keep taking your medicines as prescribed, and tell your pharmacist or doctor about both right away so your care team can adjust your dose and watch you closely.
Mechanism: Ibrexafungerp is a weak . Lomitapide is a CYP3A4 , so may increase lomitapide exposure (, ). Evidence is rated probable; onset unspecified; severity major ( and adverse effect risk).
- Maximum lomitapide dose with a weak CYP3A4 inhibitor: 30 mg (adults), 20 mg (ages 11 to 17), 10 mg (ages 2 to 10).
- If the inhibitor is started in a patient on a stable lomitapide dose, reduce the lomitapide dose by half. Titrate cautiously based on LDL-C response and tolerability, up to half the usual maximum.
- With oral contraceptives only, the maximum is about two thirds of the usual maximum dose.
- Use the labeled age-based schedules for new starts, and monitor LFTs and GI tolerability.
See the 1 reference behind this explanation ↓
From the HelloPharmacist Pharmacy Team
AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .
How we build these pages · How we use AI · Our editorial policy
Why Lomitapide and Ibrexafungerp Interact
The likely mechanism
of -mediated of lomitapide
How to Manage the Lomitapide and Ibrexafungerp Interaction
Your care team can manage this by tailoring your lomitapide dose and monitoring you.
- Keep taking both medicines exactly as prescribed, and do not change a dose on your own.
- If you are already on a stable lomitapide dose, your prescriber may reduce it by about half when ibrexafungerp starts, then adjust carefully based on your LDL cholesterol response and how you tolerate it.
- If you are starting lomitapide, the dose may be raised more slowly, with a lower maximum dose than usual.
- Tell your prescriber or pharmacist if you also take oral contraceptives, since the dose limit may differ.
- Report nausea, diarrhea, belly pain, or signs of liver trouble (yellow skin or eyes, dark urine) promptly.
Management is individual — confirm any change with your pharmacist or prescriber.
Questions for Your Pharmacist
- Does my dose of Lomitapide or Ibrexafungerp need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there another option that avoids this interaction?
Literature Reports
1 report from the published literature. Each one is headed by the title of the published study it comes from.
What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.
-
Report 1 · Study title
Prescribing information: JUXTAPID oral capsules, lomitapide oral capsules
When atorvastatin (a weak ) 80 mg daily was given together with a single 20 mg dose of lomitapide, the lomitapide rose 2-fold and its rose 2.1-fold, relative to lomitapide given alone.1
Lomitapide and Ibrexafungerp: Common Questions
How serious is the Lomitapide and Ibrexafungerp interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How is the Lomitapide and Ibrexafungerp interaction managed?
Your care team can manage this by tailoring your lomitapide dose and monitoring you. Keep taking both medicines exactly as prescribed, and do not change a dose on your own. If you are already on a stable lomitapide dose, your prescriber may reduce it by about half when ibrexafungerp starts, then adjust carefully based on your LDL cholesterol response and how you tolerate it. If you are starting lo… Management is individual — always follow your own care team's guidance.
Does taking Lomitapide and Ibrexafungerp at different times of day help?
No. Taking them at different times of day does not prevent this one. Ibrexafungerp slows , an enzyme that breaks down lomitapide, so lomitapide can build up in the body. That change lasts while ibrexafungerp is being taken and can continue for a while after the last dose.
Your pharmacist or prescriber can tell you how they will manage it.
Who is at higher risk from the Lomitapide and Ibrexafungerp interaction?
The interaction record names this group as more likely to be affected:
- People taking higher doses
If this describes you, tell your pharmacist or prescriber.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Ask About the Lomitapide and Ibrexafungerp Interaction
Ask in your own words about taking Lomitapide and Ibrexafungerp together. The answer comes from this page’s interaction record and both drugs’ own information.
This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.
AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.
References (1)
- Product Information: JUXTAPID® oral capsules, lomitapide oral capsules. Chiesi USA, Inc. (per Manufacturer), Cary, NC, 2026. DailyMed
Other Serious Interactions of Lomitapide and Ibrexafungerp
Also serious with Lomitapide
- Ketoconazole TopicalContraindicated
- LefamulinContraindicated
- Lenacapavir OralContraindicated
- Letermovir InjectionContraindicated
Also serious with Ibrexafungerp
These Medications Also Interact With Supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
With Lomitapide
- GrapefruitMajor
- St. John's WortMajor
- Activated CharcoalMajor
- WineMajor
- BeerMajor
- Siberian CockleburMajor
- Vitamin EModerate
- Vitamin AModerate
- + 164 more
Check everything you take with our drug–supplement interaction checker.
Still Have Questions About This Combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
About This Library
Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →
What Each Rating Means
Severity Levels
- Contraindicated These should generally not be used together.
- Major Potentially serious — often needs a change or close monitoring. This interaction.
- Moderate Can be significant — usually manageable with monitoring.
- Minor Usually limited clinical impact.
Evidence Grades
- EstablishedWell documented — supported by controlled studies or strong clinical data.
- ProbableGood supporting evidence, though not definitively proven. This interaction.
- SuspectedSome evidence suggests this interaction, but it is not well established.
- PossibleLimited or conflicting evidence; the interaction may occur.
- TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.
How Soon It Shows
- RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
- DelayedEffects tend to build up gradually over days to weeks.
- UnspecifiedThe timing of this interaction is not well characterized. This interaction.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.